Condition: Hepatocellular Carcinoma · Biliary Tract Cancer · Sponsor: Tongji Hospital
Exploring the precise medicine of patients with primary hepatobiliary cancer. And evaluate the efficacy and safety of individualized treatment regimens for primary hepatobiliary cancer based on next-generation sequencing.
This description comes directly from the study's public registry record.
Bixiang Zhang, PhD · 86-027-83665293 · bixiangzhang@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05520788